Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies
NCT06909474
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
15
Enrollment
INDUSTRY
Sponsor class
Conditions
T-ALL/Lymphoma
Interventions
BIOLOGICAL:
Anti-CD5 CAR NK cells
Sponsor
Chongqing Precision Biotech Co., Ltd